Noden Pharma Announces FDA Approval of Tekturna(R) (aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older

DUBLIN, Nov. 15, 2017 -- (Healthcare Sales & Marketing Network) -- Noden Pharma DAC, a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a broad range of therapeutic areas, announced today the approval by t... Biopharmaceuticals, Cardiology, FDA Noden Pharma, Tekturna, aliskiren, Hypertension
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news